NASH: The Epidemic Is Here, Are You Ready?
San Diego, CA - Manchester Grand Hyatt – Harbor Room Ballroom A/B/C
May 18, 2019 @ 6:15 pm
    Activity Overview

    Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), relatively unknown just 2 decades ago, are now the most common causes of chronic liver disease worldwide, affecting an estimated 25% of the world's population. The collective epidemic of NAFLD and NASH closely parallels the epidemics of obesity and type 2 diabetes mellitus. As the prevalence of these conditions continues to increase, predictions are that the prevalence of NAFLD and NASH will also increase, creating an unprecedented clinical and economic burden. Early disease can be managed with modification of risk factors in some individuals. There are no approved drug regimens to treat NASH, but the clinical trial pipeline is very active. A panel of leading experts will emphasize the importance of early detection and diagnosis as a means to halting the epidemic through either preventing progression of disease or in the future, treatment.

    Speakers
    • Kris V. Kowdley, MD, FACP, FAASLD, AGAF, FACG
      Moderator
      Director
      Liver Care Network and Organ Care Research
      Swedish Medical Center
      Seattle, Washington
    • Mitchell L. Shiffman, MD, FAASLD, FACG
      Panelist
      Director
      Bon Secours Liver Institute of Richmond
      Richmond, Virginia
      Bon Secours Liver Institute of Hampton Roads
      Hampton Roads, Virginia
    • Zobair M. Younossi, MD, MPH, FACP, FAASLD, AGAF, FACG
      Panelist
      Chairman
      Center for Liver Disease
      Department of Medicine
      Inova Fairfax Medical Campus
      Betty and Guy Beatty Center for
      Integrated Research, Inova
      Health System
      Falls Church, Virginia
    Program Saturday, May 18, 2019
    • 6:15 PM
    • Registration & Dinner
    • 6:45 PM
    • Welcome and Introductions
      Kris V. Kowdley, MD, FACP, FAASLD, AGAF, FACG
    • The Global Epidemic: The 30,000-Foot View
      Zobair M. Younossi, MD, MPH, FACP, FAASLD, AGAF, FACG
    • Identifying Patients With Advanced Fibrosis and NASH: A Case-Based Discussion
      Mitchell L. Shiffman, MD, FAASLD, FACG
    • Emerging Therapies: From MOA to Efficacy and Safety
      Kris V. Kowdley, MD, FACP, FAASLD, AGAF, FACG
    • Concluding Remarks
      Kris V. Kowdley, MD, FACP, FAASLD, AGAF, FACG
    • 8:15 PM
    • Audience Q & A
    Learning Objectives
    Upon completion of this activity, participants will:
    • Have increased knowledge regarding the
      • Burden of disease and risk factors for NASH
      • Clinical data on noninvasive modalities used to diagnose NAFLD and NASH
      • Clinical data on emerging treatments for NAFLD and NASH
    • Have greater competence related to
      • Appropriate use of noninvasive and invasive modalities used to diagnose NAFLD and NASH
    Target Audience
    This activity is intended for gastroenterologists, hepatologists, primary care physicians, diabetologists, endocrinologists and others involved in the diagnosis and treatment of NASH.
    Goal Statement
    The goal of this activity is to increase diagnosis of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), who can be managed with evidence-based strategies, including emerging therapies in the future.
    This program is not affiliated with Digestive Disease Week®
    Credits Available
    • 1.5
    • For Physicians
    Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Accreditation Statement
    In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
    San Diego
    Manchester Grand Hyatt
    Harbor Ballroom A/B/C
    1 Market Pl, San Diego, CA 92101
    Supporter
    Supported by an independent educational grant from
    Intercept Pharmaceuticals, Inc.